Synlogic, Inc. announced that it has achieved its third pre-specified research milestone and earned a third milestone payment of $2.5 million due under its collaboration agreement with Roche for the research and pre-clinical development of a Synthetic Biotic for the treatment of inflammatory bowel disease (IBD). Pursuant to the terms of the research collaboration agreement, Synlogic and Roche collaborated to develop a Synthetic Biotic to address an undisclosed novel target in IBD. Roche has the exclusive option to enter a licensing and collaboration agreement for further development and commercialization of the product candidate.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.6 USD | +1.27% | -3.03% | -58.44% |
05-14 | Synlogic, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
03-21 | Synlogic, Inc. Announces Board Changes | CI |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
230.4 CHF | -0.73% | -2.83% | 205B | ||
1.6 USD | +1.27% | -3.03% | 18.4M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-58.44% | 18.4M | |
+67.53% | 62.86B | |
-0.77% | 41.38B | |
+45.66% | 40.38B | |
-10.72% | 27.64B | |
+13.30% | 26.46B | |
-22.79% | 18.9B | |
+4.70% | 12.67B | |
+24.10% | 12.27B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- SYBX Stock
- News Synlogic, Inc.
- Synlogic, Inc. Achieves Research Milestone and Earns $2.5 Million Milestone Payment from Roche Collaboration